APIM Therapeutics is a biotechnology company dedicated to the
development of novel-cancer agents targeting DNA repair and cell
cycle control. The Company is developing a pipeline of peptide
compounds that inhibit PCNA-dependent DNA repair in cancer cells.
The lead compound, ATX-101, has shown proof-of-concept in
multiple preclinical in vitro and in vivo cancer models.
Birk Venture takes one seat in the board of Directors of the company.
